Clinical Trial

High-Flow Nasal Oxygen During Endoscopic Retrograde Cholangiopancreatography In Geriatric Patients

Study acronym: HFNO ERCP
Completed
View on ClinicalTrials.gov →
Summary
This prospective, single-centre, randomized controlled trial evaluates whether high-flow nasal oxygen (HFNO) reduces hypoxaemia compared with conventional low-flow oxygen therapy (COT) during endoscopic retrograde cholangiopancreatography (ERCP) performed under sedation in geriatric and adult patients. One hundred ASA I-III patients undergoing ERCP were stratified by age (\<65 and ≥65 years) and randomized to receive HFNO or COT. The primary outcome is the incidence of hypoxaemia (SpO₂ ≤90%). Secondary outcomes include hypotension, haemodynamic changes, sedative consumption, and recovery time.
Trial Details
NCT Number NCT07493811
Lead Sponsor Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Conditions Hypoxemia, Hemodynamic Instability
Enrollment 100 participants
Start Date 2025-04-15
Primary Completion 2025-10-15 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-25